{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:09:21Z","timestamp":1785470961861,"version":"3.56.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018253","name":"Corvinus University of Budapest","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018253","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>We aim to compare the measurement properties of three indirect (EQ-5D-5L, PROPr, SF-6D) and one direct (time trade-off, TTO) utility assessment methods in patients with chronic skin diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>120 patients with physician-diagnosed chronic skin diseases (psoriasis 39%, atopic dermatitis 27%, acne 19%) completed a cross-sectional survey. Respondents completed the EQ-5D-5L, PROMIS-29+2 and SF-36v1 questionnaires and a 10-year TTO task for own current health. Utilities were computed using the US value sets. Ceiling, convergent and known-group validity were compared across the utilities derived with these four methods. Known-groups were defined based on general, physical and mental health. The agreement between utilities was assessed using intraclass correlation coefficients (ICC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Mean utilities for the EQ-5D-5L, PROPr, SF-6D and TTO were 0.79, 0.47, 0.76 and 0.89. In corresponding order, the ceiling was 28%, 0%, 2% and 65%. The SF-6D showed excellent agreement with the EQ-5D-5L (ICC\u2009=\u20090.770). PROPr demonstrated poor agreement with the EQ-5D-5L (ICC\u2009=\u20090.381) and fair with SF-6D utilities (ICC\u2009=\u20090.445). TTO utilities showed poor agreement with indirectly assessed utilities (ICC\u2009=\u20090.058\u20130.242). The EQ-5D-5L better discriminated between known groups of general and physical health, while the SF-6D and PROPr outperformed the EQ-5D-5L for mental health problems.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There is a great variability in utilities across the four methods in patients with chronic skin conditions. The EQ-5D-5L, despite its higher ceiling, appears to be the most efficient in discriminating between patient groups for physical health aspects. Our findings inform the choice of instrument for quality-adjusted life year calculations in cost-utility analyses.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10198-024-01728-5","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T06:01:53Z","timestamp":1727503313000},"page":"627-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2386-4525","authenticated-orcid":false,"given":"\u00c1kos","family":"Szab\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6095-2295","authenticated-orcid":false,"given":"Valentin","family":"Brodszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9674-620X","authenticated-orcid":false,"given":"Fanni","family":"Rencz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"12","key":"1728_CR1","doi-asserted-by":"publisher","first-page":"adv00161","DOI":"10.2340\/00015555-3511","volume":"100","author":"F Ali","year":"2020","unstructured":"Ali, F., Vyas, J., Finlay, A.Y.: Counting the Burden: Atopic dermatitis and health-related quality of life. Acta dermato-venereologica. 100(12), adv00161 (2020). https:\/\/doi.org\/10.2340\/00015555-3511","journal-title":"Acta dermato-venereologica"},{"issue":"20","key":"1728_CR2","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2021.17633","volume":"326","author":"DZ Eichenfield","year":"2021","unstructured":"Eichenfield, D.Z., Sprague, J., Eichenfield, L.F.: Management of Acne Vulgaris: A review. Jama. 326(20), 2055\u20132067 (2021). https:\/\/doi.org\/10.1001\/jama.2021.17633","journal-title":"Jama"},{"issue":"Suppl 2","key":"1728_CR3","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64 Suppl 2","author":"RG Langley","year":"2005","unstructured":"Langley, R.G., Krueger, G.G., Griffiths, C.E.: Psoriasis: Epidemiology, clinical features, and quality of life. Ann. Rheum. Dis. 64(Suppl 2), ii18\u201323 (2005). https:\/\/doi.org\/10.1136\/ard.2004.033217","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"1728_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s13671-017-0192-7","volume":"6","author":"D Seth","year":"2017","unstructured":"Seth, D., Cheldize, K., Brown, D., Freeman, E.F.: Global burden of skin disease: Inequities and innovations. Curr. Dermatology Rep. 6(3), 204\u2013210 (2017). https:\/\/doi.org\/10.1007\/s13671-017-0192-7","journal-title":"Curr. Dermatology Rep."},{"key":"1728_CR5","doi-asserted-by":"publisher","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017: Lancet (London England). 392(10159), 1789\u20131858 (2018). https:\/\/doi.org\/10.1016\/s0140-6736(18)32279-7","DOI":"10.1016\/s0140-6736(18)32279-7"},{"issue":"1","key":"1728_CR6","doi-asserted-by":"publisher","first-page":"e0189765","DOI":"10.1371\/journal.pone.0189765","volume":"13","author":"C Kromer","year":"2018","unstructured":"Kromer, C., Sonntag, C.D., Peitsch, D.: Biologicals and small molecules in psoriasis: A systematic review of economic evaluations. PloS One. 13(1), e0189765 (2018). https:\/\/doi.org\/10.1371\/journal.pone.0189765","journal-title":"PloS One"},{"key":"1728_CR7","doi-asserted-by":"crossref","unstructured":"Brazier, J., Ratcliffe, J., Saloman, J., Tsuchiya, A.: Measuring and Valuing Health Benefits for Economic Evaluation. Oxford University Press (2017)","DOI":"10.1093\/med\/9780198725923.001.0001"},{"key":"1728_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-publhealth-052120-012811","volume":"43","author":"RM Kaplan","year":"2022","unstructured":"Kaplan, R.M., Hays, R.D.: Health-Related Quality of Life Measurement in Public Health. Annu. Rev. Public Health. 43, 355\u2013373 (2022). https:\/\/doi.org\/10.1146\/annurev-publhealth-052120-012811","journal-title":"Annu. Rev. Public Health"},{"issue":"6","key":"1728_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0021-9681(87)90019-1","volume":"40","author":"GW Torrance","year":"1987","unstructured":"Torrance, G.W.: Utility approach to measuring health-related quality of life. J. Chronic Dis. 40(6), 593\u2013603 (1987). https:\/\/doi.org\/10.1016\/0021-9681(87)90019-1","journal-title":"J. Chronic Dis."},{"issue":"Suppl 1","key":"1728_CR10","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1007\/s10198-013-0508-x","volume":"14 Suppl 1","author":"AE Attema","year":"2013","unstructured":"Attema, A.E., Edelaar-Peeters, Y., Versteegh, M.M., Stolk, E.A.: Time trade-off: One methodology, different methods. Eur. J. Health Eco. 14(Suppl 1), S53\u201364 (2013). https:\/\/doi.org\/10.1007\/s10198-013-0508-x","journal-title":"Eur. J. Health Economics: HEPAC : Health Econ. Prev. care"},{"issue":"8","key":"1728_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s11136-015-0926-6","volume":"24","author":"J Richardson","year":"2015","unstructured":"Richardson, J., Iezzi, A., Khan, M.A.: Why do multi-attribute utility instruments produce different utilities: The relative importance of the descriptive systems, scale and \u2018micro-utility\u2019 effects. Qual. Life Res.\u00a024(8), 2045\u20132053 (2015). https:\/\/doi.org\/10.1007\/s11136-015-0926-6","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"Suppl 1","key":"1728_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40273-017-0544-y","volume":"35","author":"D Rowen","year":"2017","unstructured":"Rowen, D., Azzabi Zouraq, I., Chevrou-Severac, H., van Hout, B.: International Regulations and Recommendations for Utility Data for Health Technology Assessment. PharmacoEconomics. 35(Suppl 1), 11\u201319 (2017). https:\/\/doi.org\/10.1007\/s40273-017-0544-y","journal-title":"PharmacoEconomics"},{"issue":"Suppl 1","key":"1728_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40273-017-0545-x","volume":"35","author":"J Brazier","year":"2017","unstructured":"Brazier, J., Ara, R., Rowen, D., Chevrou-Severac, H.: A review of generic preference-based measures for use in cost-effectiveness models. PharmacoEconomics. 35(Suppl 1), 21\u201331 (2017). https:\/\/doi.org\/10.1007\/s40273-017-0545-x","journal-title":"PharmacoEconomics"},{"issue":"11","key":"1728_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s40273-023-01293-4","volume":"41","author":"KC Heinz","year":"2023","unstructured":"Heinz, K.C., Beaudart, C., Willems, D., Wiethoff, I., Hiligsmann, M.: Cost-effectiveness of emerging treatments for atopic dermatitis. Syst. Rev. PharmacoEconomics. 41(11), 1415\u20131435 (2023). https:\/\/doi.org\/10.1007\/s40273-023-01293-4","journal-title":"Syst. Rev. PharmacoEconomics"},{"issue":"8","key":"1728_CR15","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s13555-022-00774-2","volume":"12","author":"A Igarashi","year":"2022","unstructured":"Igarashi, A., Yuasa, A., Yonemoto, N., et al.: A Systematic Literature Review of Economic Evaluations and cost studies of the Treatment of Psoriasis, atopic dermatitis, and chronic Urticaria. Dermatology Therapy. 12(8), 1729\u20131751 (2022). https:\/\/doi.org\/10.1007\/s13555-022-00774-2","journal-title":"Dermatology Therapy"},{"key":"1728_CR16","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.ejcskn.2023.100008","volume":"1","author":"CJ Lieke","year":"2023","unstructured":"Lieke, C.J., Nicole, W.J.K.-S., Andrea, P., Klara, M., Brigitte, A.B.E.: A systematic review of economic evaluations for the interventions of superficial basal cell carcinoma. EJC Skin. Cancer. 1, 100008 (2023). https:\/\/doi.org\/10.1016\/j.ejcskn.2023.100008","journal-title":"EJC Skin. Cancer"},{"issue":"2","key":"1728_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1087-0024.2003.09112.x","volume":"9","author":"SC Chen","year":"2004","unstructured":"Chen, S.C., Bayoumi, A.M., Soon, S.L., et al.: A catalog of dermatology utilities: A measure of the burden of skin diseases. J. Invest. Dermatology Symp. Proc. 9(2), 160\u2013168 (2004). https:\/\/doi.org\/10.1046\/j.1087-0024.2003.09112.x","journal-title":"J. Invest. Dermatology Symp. Proc."},{"issue":"9","key":"1728_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10198-014-0638-9","volume":"16","author":"Y Yang","year":"2015","unstructured":"Yang, Y., Brazier, J., Longworth, L.: EQ-5D in skin conditions: An assessment of validity and responsiveness. Eur. J. Health Economics. 16(9), 927\u2013939 (2015). https:\/\/doi.org\/10.1007\/s10198-014-0638-9","journal-title":"Eur. J. Health Economics: HEPAC : Health Econ. Prev. care"},{"issue":"1","key":"1728_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12955-022-01995-x","volume":"20","author":"G Ruzsa","year":"2022","unstructured":"Ruzsa, G., Rencz, F., Brodszky, V.: Assessment of health state utilities in dermatology: An experimental time trade-off value set for the dermatology life quality index. Health Qual. Life Outcomes. 20(1), 87 (2022). https:\/\/doi.org\/10.1186\/s12955-022-01995-x","journal-title":"Health Qual. Life Outcomes"},{"issue":"3","key":"1728_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00403-012-1309-2","volume":"305","author":"C Blome","year":"2013","unstructured":"Blome, C., Beikert, F.C., Rustenbach, S.J., Augustin, M.: Mapping DLQI on EQ-5D in psoriasis: Transformation of skin-specific health-related quality of life into utilities. Arch. Dermatol. Res. 305(3), 197\u2013204 (2013). https:\/\/doi.org\/10.1007\/s00403-012-1309-2","journal-title":"Arch. Dermatol. Res."},{"issue":"8","key":"1728_CR21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jval.2017.10.024","volume":"21","author":"NJ Davison","year":"2018","unstructured":"Davison, N.J., Thompson, A.J., Turner, A.J., et al.: Generating EQ-5D-3L utility scores from the Dermatology Life Quality Index: A mapping study in patients with psoriasis. Value Health. 21(8), 1010\u20131018 (2018). https:\/\/doi.org\/10.1016\/j.jval.2017.10.024","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"issue":"Suppl 1","key":"1728_CR22","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1007\/s10198-014-0600-x","volume":"15","author":"E Her\u00e9di","year":"2014","unstructured":"Her\u00e9di, E., Rencz, F., Balogh, O., et al.: Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. Eur J Health Econ.\u00a015(Suppl 1), S111\u2013S119 (2014). https:\/\/doi.org\/10.1007\/s10198-014-0600-x","journal-title":"Eur. J. Health Economics: HEPAC : Health Econ. Prev. care"},{"issue":"9","key":"1728_CR23","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s11136-020-02499-1","volume":"29","author":"AW Vilsb\u00f8ll","year":"2020","unstructured":"Vilsb\u00f8ll, A.W., Kragh, N., Hahn-Pedersen, J., Jensen, C.E.: Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study. Quality of Life Research.\u00a029(9), 2529\u20132539 (2020). https:\/\/doi.org\/10.1007\/s11136-020-02499-1","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"2","key":"1728_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/jdv.14584","volume":"32","author":"MM Balp","year":"2018","unstructured":"Balp, M.M., Khalil, S., Tian, H., Gabriel, S., Vietri, J., Zuberbier, T.: Burden of chronic urticaria relative to psoriasis in five European countries. J. Eur. Acad. Dermatology Venereology\u00a032(2), 282\u2013290 (2018). https:\/\/doi.org\/10.1111\/jdv.14584","journal-title":"J. Eur. Acad. Dermatology Venereology: JEADV"},{"key":"1728_CR25","doi-asserted-by":"publisher","unstructured":"Hirvonen, M.J., Pasternack, R., Lipits\u00e4, T., et al.: Patients with Hidradenitis Suppurativa Suffer from Low Health-Related Quality of Life as measured by the generic 15D instrument. Skin appendage disorders. 8(3):221\u2013227. (2022). https:\/\/doi.org\/10.1159\/000520839","DOI":"10.1159\/000520839"},{"issue":"1","key":"1728_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/bjd.18002","volume":"182","author":"JI Silverberg","year":"2020","unstructured":"Silverberg, J.I., Margolis, D.J., Boguniewicz, M., et al.: Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Br. J. Dermatol. 182(1), 104\u2013111 (2020). https:\/\/doi.org\/10.1111\/bjd.18002","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"1728_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jval.2023.02.002","volume":"26","author":"F Rencz","year":"2023","unstructured":"Rencz, F., Brodszky, V., Janssen, M.F.: A direct comparison of the Measurement properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr utilities in a General Population Sample. Value Health. 26(7), 1045\u20131056 (2023). https:\/\/doi.org\/10.1016\/j.jval.2023.02.002","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"issue":"9","key":"1728_CR28","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.2215\/cjn.01880221","volume":"16","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Dewitt, B., Tang, E., et al.: Evaluation of PROMIS Preference Scoring System (PROPr) in patients undergoing hemodialysis or kidney transplant. Clin. J. Am. Soc. Nephrology:\u00a016(9), 1328\u20131336 (2021). https:\/\/doi.org\/10.2215\/cjn.01880221","journal-title":"Clin. J. Am. Soc. Nephrology: CJASN"},{"issue":"12","key":"1728_CR29","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/s11136-023-03486-y","volume":"32","author":"H Ahmad","year":"2023","unstructured":"Ahmad, H., Campbell, J.A., van der Mei, I., et al.: Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: Implications for health economic evaluation models. Quality of Life Research.\u00a032(12), 3373\u20133387 (2023). https:\/\/doi.org\/10.1007\/s11136-023-03486-y","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"1","key":"1728_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12955-023-02216-9","volume":"21","author":"T Pan","year":"2023","unstructured":"Pan, T., Wu, Y., Buchanan, J., Goranitis, I.: QALYs and rare diseases: Exploring the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing for childhood and adult-onset rare genetic conditions in Australia. Health Qual. Life Outcomes. 21(1), 132 (2023). https:\/\/doi.org\/10.1186\/s12955-023-02216-9","journal-title":"Health Qual. Life Outcomes"},{"issue":"3","key":"1728_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0272989x14543107","volume":"35","author":"J Richardson","year":"2015","unstructured":"Richardson, J., Khan, M.A., Iezzi, A., Maxwell, A.: Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments. Med. Decis. Making.\u00a035(3), 276\u2013291 (2015). https:\/\/doi.org\/10.1177\/0272989x14543107","journal-title":"Med. Decis. Making: Int. J. Soc. Med. Decis. Mak."},{"key":"1728_CR32","doi-asserted-by":"publisher","unstructured":"Bat\u00f3, A., Brodszky, V., Gergely, L.H., et al.: The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual. Life Res. 30(5):1477\u20131490. (2021). https:\/\/doi.org\/10.1007\/s11136-020-02732-x","DOI":"10.1007\/s11136-020-02732-x"},{"issue":"1","key":"1728_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10198-022-01460-y","volume":"24","author":"K Koszor\u00fa","year":"2023","unstructured":"Koszor\u00fa, K., Hajdu, K., Brodszky, V., et al.: Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis. Eur. J. Health Eco.\u00a024(1), 139\u2013152 (2023). https:\/\/doi.org\/10.1007\/s10198-022-01460-y","journal-title":"Eur. J. Health Economics: HEPAC : Health Econ. Prev. care"},{"issue":"12","key":"1728_CR34","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s11136-017-1699-x","volume":"26","author":"AK Po\u00f3r","year":"2017","unstructured":"Po\u00f3r, A.K., Rencz, F., Brodszky, V., et al.: Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual. Life Res.\u00a026(12), 3409\u20133419 (2017). https:\/\/doi.org\/10.1007\/s11136-017-1699-x","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"12","key":"1728_CR35","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.jval.2022.06.012","volume":"25","author":"F Rencz","year":"2022","unstructured":"Rencz, F., Janssen, M.F.: Analyzing the Pain\/Discomfort and Anxiety\/Depression composite domains and the meaning of discomfort in the EQ-5D: A mixed-methods study. Value Health.\u00a025(12), 2003\u20132016 (2022). https:\/\/doi.org\/10.1016\/j.jval.2022.06.012","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"1728_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01610-w","author":"A Bat\u00f3","year":"2023","unstructured":"Bat\u00f3, A., Brodszky, V., Mitev, A.Z., Jenei, B., Rencz, F.: Psychometric properties and general population reference values for PROMIS Global Health in Hungary. Eur. J. Health Eco. (2023). https:\/\/doi.org\/10.1007\/s10198-023-01610-w","journal-title":"Eur. J. Health Economics: HEPAC : Health Econ. Prev. care"},{"issue":"8","key":"1728_CR37","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s11136-023-03364-7","volume":"32","author":"B Jenei","year":"2023","unstructured":"Jenei, B., Bat\u00f3, A., Mitev, A.Z., Brodszky, V., Rencz, F.: Hungarian PROMIS-29+2: Psychometric properties and population reference values. Qual. Life Res.\u00a032(8), 2179\u20132194 (2023). https:\/\/doi.org\/10.1007\/s11136-023-03364-7","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"key":"1728_CR38","doi-asserted-by":"crossref","unstructured":"Nikl, A., Janssen, M.F., Jenei, B., Brodszky, V., Rencz, F.: Population norms for the EQ-5D-5L, PROPr and SF-6D in Hungary. PharmacoEconomics. 42(5), 583\u2013603 (2024)","DOI":"10.1007\/s40273-024-01360-4"},{"key":"1728_CR39","doi-asserted-by":"publisher","unstructured":"EUROSTAT: European Health Interview Survey (EHIS wave 3) \u2014 Methodological manual. 10.2785\/020714. Accessed June 11:. (2018) (2021). https:\/\/doi.org\/10.2785\/020714","DOI":"10.2785\/020714"},{"issue":"9","key":"1728_CR40","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s11136-023-03418-w","volume":"32","author":"MM Angyal","year":"2023","unstructured":"Angyal, M.M., Lakatos, P.L., Jenei, B., Brodszky, V., Rencz, F.: Health utilities and willingness to pay in adult patients with coeliac disease in Hungary. Qual. Life Res.\u00a032(9), 2503\u20132516 (2023). https:\/\/doi.org\/10.1007\/s11136-023-03418-w","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"4","key":"1728_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","volume":"17","author":"M Oppe","year":"2014","unstructured":"Oppe, M., Devlin, N.J., van Hout, B., Krabbe, P.F., de Charro, F.: A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health.\u00a017(4), 445\u2013453 (2014). https:\/\/doi.org\/10.1016\/j.jval.2014.04.002","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"issue":"9","key":"1728_CR42","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.jval.2020.03.019","volume":"23","author":"F Rencz","year":"2020","unstructured":"Rencz, F., Brodszky, V., Gul\u00e1csi, L., et al.: Parallel valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value Health.\u00a023(9), 1235\u20131245 (2020). https:\/\/doi.org\/10.1016\/j.jval.2020.03.019","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"issue":"11","key":"1728_CR43","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/j.pain.0000000000001028","volume":"158","author":"F Rencz","year":"2017","unstructured":"Rencz, F., P\u00e9ntek, M., Stalmeier, P.F.M., et al.: Bleeding out the quality-adjusted life years: Evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. Pain. 158(11), 2259\u20132267 (2017). https:\/\/doi.org\/10.1097\/j.pain.0000000000001028","journal-title":"Pain"},{"issue":"Suppl 2","key":"1728_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-022-01190-2","volume":"40","author":"F Rencz","year":"2022","unstructured":"Rencz, F., Ruzsa, G., Bat\u00f3, A., Yang, Z., Finch, A.P., Brodszky, V.: Value Set for the EQ-5D-Y-3L in Hungary. PharmacoEconomics. 40(Suppl 2), 205\u2013215 (2022). https:\/\/doi.org\/10.1007\/s40273-022-01190-2","journal-title":"PharmacoEconomics"},{"issue":"10","key":"1728_CR45","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., et al.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research.\u00a020(10), 1727\u20131736 (2011). https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"8","key":"1728_CR46","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard, A.S., Law, E.H., Jiang, R., et al.: United States Valuation of EQ-5D-5L Health States using an International Protocol. Value Health.\u00a022(8), 931\u2013941 (2019). https:\/\/doi.org\/10.1016\/j.jval.2019.02.009","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"1728_CR47","doi-asserted-by":"publisher","unstructured":"Cella, D., Choi, S.W., Condon, D.M., et al.: PROMIS(\u00ae) Adult Health profiles: Efficient short-form measures of Seven Health domains. Value Health.\u00a022(5), 537\u2013544 (2019). https:\/\/doi.org\/10.1016\/j.jval.2019.02.004","DOI":"10.1016\/j.jval.2019.02.004"},{"key":"1728_CR48","doi-asserted-by":"publisher","unstructured":"Dewitt, B., Feeny, D., Fischhoff, B., et al.: Estimation of a preference-based Summary score for the patient-reported outcomes Measurement Information System: The PROMIS(\u00ae)-Preference (PROPr) Scoring System. Med. Decis. Making.\u00a038(6), 683\u2013698 (2018). https:\/\/doi.org\/10.1177\/0272989x18776637","DOI":"10.1177\/0272989x18776637"},{"issue":"6","key":"1728_CR49","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware, J.E. Jr., Sherbourne, C.D.: The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med. Care. 30(6), 473\u2013483 (1992)","journal-title":"Med. Care"},{"issue":"6","key":"1728_CR50","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0272989x13482524","volume":"33","author":"BM Craig","year":"2013","unstructured":"Craig, B.M., Pickard, A.S., Stolk, E., Brazier, J.E.: US valuation of the SF-6D. Med. Decis. Making. 33(6), 793\u2013803 (2013). https:\/\/doi.org\/10.1177\/0272989x13482524","journal-title":"Med. Decis. Making: Int. J. Soc. Med. Decis. Mak."},{"issue":"7","key":"1728_CR51","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","volume":"18","author":"RD Hays","year":"2009","unstructured":"Hays, R.D., Bjorner, J.B., Revicki, D.A., Spritzer, K.L., Cella, D.: Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual. Life Res.\u00a018(7), 873\u2013880 (2009). https:\/\/doi.org\/10.1007\/s11136-009-9496-9","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"1","key":"1728_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee, C.B., Bot, S.D., de Boer, M.R., et al.: Quality criteria were proposed for measurement properties of health status questionnaires. J. Clin. Epidemiol. 60(1), 34\u201342 (2007). https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"1728_CR53","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","volume":"30","author":"YS Feng","year":"2021","unstructured":"Feng, Y.S., Kohlmann, T., Janssen, M.F., Buchholz, I.: Psychometric properties of the EQ-5D-5L: A systematic review of the literature. Quality of Life Research.\u00a030(3), 647\u2013673 (2021). https:\/\/doi.org\/10.1007\/s11136-020-02688-y","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"key":"1728_CR54","unstructured":"Evans, J.D.: Straightforward Statistics for the Behavioral Sciences. Thomson Brooks\/Cole Publishing Co (1996)"},{"issue":"5","key":"1728_CR55","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jval.2021.10.012","volume":"25","author":"CP Klapproth","year":"2022","unstructured":"Klapproth, C.P., Sidey-Gibbons, C.J., Valderas, J.M., Rose, M., Fischer, F.: Comparison of the PROMIS Preference score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany. Value Health. 25(5), 824\u2013834 (2022). https:\/\/doi.org\/10.1016\/j.jval.2021.10.012","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"issue":"3","key":"1728_CR56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40273-021-01109-3","volume":"40","author":"T Pan","year":"2022","unstructured":"Pan, T., Mulhern, B., Viney, R., Norman, R., Hanmer, J., Devlin, N.: A comparison of PROPr and EQ-5D-5L value sets. PharmacoEconomics. 40(3), 297\u2013307 (2022). https:\/\/doi.org\/10.1007\/s40273-021-01109-3","journal-title":"PharmacoEconomics"},{"issue":"8","key":"1728_CR57","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s11136-017-1559-8","volume":"26","author":"FA Sayah","year":"2017","unstructured":"Sayah, F.A., Qiu, W., Xie, F., Johnson, J.A.: Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes. Quality of Life Research. 26(8), 2057\u20132066 (2017). https:\/\/doi.org\/10.1007\/s11136-017-1559-8","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"1","key":"1728_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12955-023-02204-z","volume":"21","author":"RH Xu","year":"2023","unstructured":"Xu, R.H., Ma, B., Xin, H., et al.: Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy. Health Qual. Life Outcomes. 21(1), 123 (2023). https:\/\/doi.org\/10.1186\/s12955-023-02204-z","journal-title":"Health Qual. Life Outcomes"},{"key":"1728_CR59","doi-asserted-by":"publisher","unstructured":"Mulhern, B.J., Pan, T., Norman, R., et al.: U measurement relationship between EQ-5D-5L, PROMIS-29 and PROPr. Quality of Life Research. 32(11), 3147\u20133160. (2023) https:\/\/doi.org\/10.1007\/s11136-023-03462-6","DOI":"10.1007\/s11136-023-03462-6"},{"issue":"9","key":"1728_CR60","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hec.866","volume":"13","author":"J Brazier","year":"2004","unstructured":"Brazier, J., Roberts, J., Tsuchiya, A., Busschbach, J.: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13(9), 873\u2013884 (2004). https:\/\/doi.org\/10.1002\/hec.866","journal-title":"Health Econ."},{"issue":"4","key":"1728_CR61","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","volume":"6","author":"DV Cicchetti","year":"1994","unstructured":"Cicchetti, D.V.: Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol. Assess. 6(4), 284\u2013290 (1994). https:\/\/doi.org\/10.1037\/1040-3590.6.4.284","journal-title":"Psychol. Assess."},{"key":"1728_CR62","doi-asserted-by":"publisher","unstructured":"Shrout, P.E., Fleiss, J.L.: Intraclass correlations: Uses in assessing rater reliability. Psychol. Bull. 86(2), 420\u2013428 (1979). https:\/\/doi.org\/10.1037\/\/0033-2909.86.2.420","DOI":"10.1037\/\/0033-2909.86.2.420"},{"issue":"8476","key":"1728_CR63","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland, J.M., Altman, D.G.: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (London England). 1(8476), 307\u2013310 (1986)","journal-title":"Lancet (London England)"},{"issue":"2","key":"1728_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11613\/BM.2015.015","volume":"25","author":"D Giavarina","year":"2015","unstructured":"Giavarina, D.: Understanding bland altman analysis. Biochemia Med. 25(2), 141\u2013151 (2015)","journal-title":"Biochemia Med."},{"key":"1728_CR65","doi-asserted-by":"publisher","unstructured":"Arnold, D., Girling, A., Stevens, A., Lilford, R.: Comparison of direct and indirect methods of estimating health state utilities for resource allocation: Review and empirical analysis. BMJ (Clinical Res. ed). 339(b2688) (2009). https:\/\/doi.org\/10.1136\/bmj.b2688","DOI":"10.1136\/bmj.b2688"},{"key":"1728_CR66","doi-asserted-by":"crossref","unstructured":"Cohen, J.: Statistical Power Analysis for the Behavioral Sciences. Academic (2013)","DOI":"10.4324\/9780203771587"},{"key":"1728_CR67","unstructured":"Tomczak, M., Tomczak, E.: The need to report effect size estimates revisited. An overview of some recommended measures of effect size. Tren Sport Sci. 21(1), 19\u201325. (2024)"},{"issue":"4","key":"1728_CR68","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjd.16883","volume":"180","author":"B Tam\u00e1si","year":"2019","unstructured":"Tam\u00e1si, B., Brodszky, V., P\u00e9ntek, M., et al.: Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. Br. J. Dermatol. 180(4), 802\u2013809 (2019). https:\/\/doi.org\/10.1111\/bjd.16883","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"1728_CR69","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s11136-022-03141-y","volume":"31","author":"F Rencz","year":"2022","unstructured":"Rencz, F., Mukuria, C., Bat\u00f3, A., Po\u00f3r, A.K., Finch, A.P.: A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. Quality of Life Research. 31(10), 3049\u20133060 (2022). https:\/\/doi.org\/10.1007\/s11136-022-03141-y","journal-title":"Quality of Life Research"},{"issue":"8","key":"1728_CR70","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jval.2013.10.003","volume":"16","author":"P Swinburn","year":"2013","unstructured":"Swinburn, P., Lloyd, A., Boye, K.S., Edson-Heredia, E., Bowman, L., Janssen, B.: Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: Lessons learned from a feasibility study in the UK. Value Health.\u00a016(8), 1156\u20131162 (2013). https:\/\/doi.org\/10.1016\/j.jval.2013.10.003","journal-title":"Value in Health"},{"issue":"1","key":"1728_CR71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11136-023-03519-6","volume":"33","author":"E Szl\u00e1vicz","year":"2024","unstructured":"Szl\u00e1vicz, E., Szab\u00f3, \u00c1., Kiny\u00f3, \u00c1., et al.: Content validity of the EQ-5D-5L with skin irritation and self-confidence bolt-ons in patients with atopic dermatitis: A qualitative think-aloud study. Quality of Life Research.\u00a033(1), 101\u2013111 (2024). https:\/\/doi.org\/10.1007\/s11136-023-03519-6","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"11","key":"1728_CR72","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/jdv.15765","volume":"33","author":"K Hajdu","year":"2019","unstructured":"Hajdu, K., Brodszky, V., Stalmeier, P.F.M., et al.: Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. J. Eur. Acad. Dermatology Venereology\u00a033(11), 2106\u20132113 (2019). https:\/\/doi.org\/10.1111\/jdv.15765","journal-title":"J. Eur. Acad. Dermatology Venereology: JEADV"},{"key":"1728_CR73","doi-asserted-by":"publisher","unstructured":"Jantarakolica T., Wanitphakdeedecha R., Yan C., et al: Willingness to Pay and Time Trade-off in Thai Patients with Port-Wine Stains. ClinicoEconomics and outcomes research. 14:635\u2013642. (2022) https:\/\/doi.org\/10.2147\/ceor.S382735","DOI":"10.2147\/ceor.S382735"},{"issue":"1","key":"1728_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/cod.12863","volume":"78","author":"D K\u00fcster","year":"2018","unstructured":"K\u00fcster, D., Haufe, E., Rethberg, C., Bauer, A., Seidler, A., Schmitt, J.: Health utilities for controlled and uncontrolled chronic hand eczema in healthcare employees. Contact Dermat. 78(1), 18\u201327 (2018). https:\/\/doi.org\/10.1111\/cod.12863","journal-title":"Contact Dermat."},{"key":"1728_CR75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-5945-11-16","volume":"11","author":"C Leeyaphan","year":"2011","unstructured":"Leeyaphan, C., Wanitphakdeedecha, R., Manuskiatti, W., Kulthanan, K.: Measuring melasma patients\u2019 quality of life using willingness to pay and time trade-off methods in Thai population. BMC Dermatol. 11, 16 (2011). https:\/\/doi.org\/10.1186\/1471-5945-11-16","journal-title":"BMC Dermatol."},{"issue":"5","key":"1728_CR76","first-page":"46","volume":"12","author":"MBC Maymone","year":"2019","unstructured":"Maymone, M.B.C., Rajanala, S., Widjajahakim, R., Secemsky, E., Saade, D., Vashi, N.A.: Willingness-to-pay and Time Trade-off: The Burden of Disease in patients with Benign Hyperpigmentation. J. Clin. Aesthetic Dermatol. 12(5), 46\u201348 (2019)","journal-title":"J. Clin. Aesthetic Dermatol."},{"issue":"1","key":"1728_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00403-017-1794-4","volume":"310","author":"AK Po\u00f3r","year":"2018","unstructured":"Po\u00f3r, A.K., Brodszky, V., P\u00e9ntek, M., et al.: Is the DLQI appropriate for medical decision-making in psoriasis patients? Arch. Dermatol. Res. 310(1), 47\u201355 (2018). https:\/\/doi.org\/10.1007\/s00403-017-1794-4","journal-title":"Arch. Dermatol. Res."},{"issue":"2","key":"1728_CR78","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2133.2007.08354.x","volume":"158","author":"J Schmitt","year":"2008","unstructured":"Schmitt, J., Meurer, M., Klon, M., Frick, K.D.: Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: A population-based study. Br. J. Dermatol. 158(2), 351\u2013359 (2008). https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08354.x","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"1728_CR79","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2012.50","volume":"132","author":"AM Seidler","year":"2012","unstructured":"Seidler, A.M., Bayoumi, A.M., Goldstein, M.K., Cruz, P.D. Jr., Chen, S.C.: Willingness to pay in dermatology: Assessment of the burden of skin diseases. J. Invest. Dermatol. 132(7), 1785\u20131790 (2012). https:\/\/doi.org\/10.1038\/jid.2012.50","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"1728_CR80","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1046\/j.1365-2133.1999.03207.x","volume":"141","author":"L Lundberg","year":"1999","unstructured":"Lundberg, L., Johannesson, M., Silverdahl, M., Hermansson, C., Lindberg, M.: Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br. J. Dermatol. 141(6), 1067\u20131075 (1999). https:\/\/doi.org\/10.1046\/j.1365-2133.1999.03207.x","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"1728_CR81","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1046\/j.1365-2133.2002.04613.x","volume":"146","author":"R Schiffner","year":"2002","unstructured":"Schiffner, R., Brunnberg, S., Hohenleutner, U., Stolz, W., Landthaler, M.: Willingness to pay and time trade-off: Useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br. J. Dermatol. 146(3), 440\u2013447 (2002). https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04613.x","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"1728_CR82","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s11136-020-02712-1","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang, R., Shaw, J., M\u00fchlbacher, A., et al.: Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off. Qual Life Res.\u00a030(5), 1433\u20131444 (2021). https:\/\/doi.org\/10.1007\/s11136-020-02712-1","journal-title":"Qual. life Research: Int. J. Qual. life Aspects Treat. care Rehabilitation"},{"issue":"6","key":"1728_CR83","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza, L.S., Stewart, K.D., Lloyd, A.J., Rowen, D., Brazier, J.E.: Vignette-based utilities: Usefulness, limitations, and methodological recommendations. Value Health. 24(6), 812\u2013821 (2021). https:\/\/doi.org\/10.1016\/j.jval.2020.12.017","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"1728_CR84","doi-asserted-by":"crossref","unstructured":"Devlin, N., Roudijk, B., Ludwig, K. (eds.): Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Springer (2022) ISBN: 978-3-030-89288-3","DOI":"10.1007\/978-3-030-89289-0"},{"issue":"6","key":"1728_CR85","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamadermatol.2020.0394","volume":"156","author":"A Patel","year":"2020","unstructured":"Patel, A., Jafferany, M.: Multidisciplinary and holistic models of care for patients with dermatologic Disease and Psychosocial Comorbidity: A systematic review. JAMA Dermatology. 156(6), 686\u2013694 (2020). https:\/\/doi.org\/10.1001\/jamadermatol.2020.0394","journal-title":"JAMA Dermatology"},{"issue":"4","key":"1728_CR86","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jval.2021.11.1361","volume":"25","author":"T Peasgood","year":"2022","unstructured":"Peasgood, T., Mukuria, C., Brazier, J., et al.: Developing a New Generic Health and Wellbeing measure: Psychometric survey results for the EQ-HWB. Value Health. 25(4), 525\u2013533 (2022). https:\/\/doi.org\/10.1016\/j.jval.2021.11.1361","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"issue":"7","key":"1728_CR87","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jval.2024.03.2195","volume":"27","author":"F Rencz","year":"2024","unstructured":"Rencz, F., Janssen, M.F.: Testing the Psychometric properties of 9 bolt-ons for the EQ-5D-5L in a General Population Sample. Value Health. 27(7), 943\u2013954 (2024). https:\/\/doi.org\/10.1016\/j.jval.2024.03.2195","journal-title":"Value Health: J. Int. Soc. Pharmacoeconomics Outcomes Res."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01728-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-024-01728-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01728-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:40:38Z","timestamp":1748684438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-024-01728-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1007\/s10198-024-01728-5","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the Research Ethics Committee of the Corvinus University of Budapest (no. KRH\/343\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Fanni Rencz is a member of the EuroQol Group. The views expressed in this article are those of the authors and do not necessarily reflect those of the EuroQol Research Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}